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Background: The long term outcome of advanced sarcoma patients treated with trabectedin outside of clinical
trials and the utility of maintenance treatment has not been reported.
Methods: Between 2003 and 2008, patients with advanced sarcoma failing doxorubicin could be treated within a
compassionate use program (ATU, Temporary Use Authorization) of trabectedin in France using the standard
3-weekly regimen. Data from 181 patients (55%) were collected from 11 centres and analyzed.
Results: Trabectedin was given in first, second, third or fourth line in metastatic phase in 6%, 37%, 33% and 23% of
patients respectively. With a median follow-up of 6 years, median PFS and OS were 3.6 months and 16.1 months
respectively. The median number of cycles was 3 (range 1–19). Best response were partial response (PR, n = 18,
10%), stable disease (SD, n = 69, 39%) and progressive disease (PD, n = 83, 46%), non evaluable (NE, n = 9, 5%). Thirty
patients (17%) had to be hospitalized for treatment- related side effects. Independent prognostic factors in
multivariate analysis (Cox model) were myxoid LPS and line of trabectedin for PFS, and myxoid LPS and
retroperitoneal sarcomas for OS. Patients in PR or SD after 6 cycles continuing treatment had a better PFS
(median 5.3 vs 10.5 months, p = 0.001) and OS (median 13.9 vs 33.4 months, p = 0.009) as compared to patients
who stopped after 6 cycles.
Conclusions: In this compassionate use program, trabectedin yielded similar or better PFS and OS than in clinical
trials. Maintenance treatment beyond 6 cycles was associated with an improved survival.* Correspondence: jean-yves.blay@lyon.unicancer.fr
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Soft tissue sarcoma (STS) constitutes a heterogeneous
group of rare cancers, with heterogeneous clinical presen-
tation, histological subtypes and molecular alterations [1].
The established standard of care for unresectable STS in
first line is doxorubicin-based chemotherapy, with typical
response rates ranging from 10% to 30% [1-4]. For patients
who relapse or develop resistance, other therapeutic
options were limited before the availability of trabectedin
[5]. For these patients, progression-free survival (PFS) and
overall survival (OS) rarely exceed 6 months and 1 year
respectively [5].
Trabectedin is a tetrahydroisoquinolone alkaloid iso-
lated from the marine organism Ecteinascidia turbinata,
a tunicate originally extracted from the Caribbean Sea.
Its complex mechanism of action involves a covalent bond
to the minor groove of double-stranded DNA, resulting in
an inhibition of gene activation and nucleotide excision
repair (NER) mechanism, and also inducing lethal DNA
double-strand breaks and cell cycle arrest in S and G2
phases [6-11]. In vitro, trabectedin has shown potent
cytotoxic activity against a variety of human STS cell lines,
and antitumor activity against a variety of human xeno-
grafts, including sarcomas, with limited cross-resistance
between trabectedin and other cytotoxic agents [11-15].
In clinical trials, single-agent trabectedin has shown
activity in a variety of tumor types, including sarcomas,
breast cancer, and ovarian cancer [16-28]. The clinical
activity of single-agent trabectedin has been demonstrated
in heavily pretreated patients with advanced STS, with
a median duration of response of 9 to 12 months and
6-months PFS rates ranging from 24% to 29% [16-24],
as well as in first line patients, either as single agent or
in combination with doxorubicin [25,26]. The STS201
randomized, open-label study was conducted in adult
STS patients with unresectable/metastatic liposarcoma
or leiomyosarcoma, after failure of prior conventional
chemotherapy including anthracyclins and ifosfamidei.
Patients were randomly assigned to one of two trabectedin
regimens (given intravenously at a dose of 1.5 mg/m2 on a
24-h infusion every 3 weeks or at a dose of 0.58 mg/m2 on
a 3-h infusion weekly for 3 weeks of a 4-week cycle). The
study met its primary endpoint with a median TTP of
3.7 months in the 24-h arm vs. 2.3 months in the 3-h arm
(p = 0.0302), showing a statistically significant 27% reduc-
tion in the risk of progression with the 24-h trabectedin
arm [27]. According to these results, trabectedin was
approved in September 2007 in the European Union for
patients with advanced STS after failure of anthracyclins
or ifosfamide or for those who are unsuited to receive
such agents. Before that date, a compassionate use pro-
gram (ATU) was set up in France where 328 patients
were included since 2003. The efficacy of trabectedin in
compassionate use programs may be different from thoseobtained in clinical trials, because patients with less favor-
able clinical characteristics are included.
Hereby are reported the results of a retrospective study
in which the outcome of patients included in this com-
passionate use program population was analyzed. The
survival and response rates of these patients were com-
parable to those reported in clinical trials. Interestingly,
maintenance treatment after 6 cycles was associated with




From 2003 to 2008, 87 centres in France enrolled included
at least one patient in the ATU (“Autorisation Temporaire
d’Utilisation”) program, a compassionate use program for
STS patients matching the inclusion criteria (see below).
Requests for participation were sent to all 43 centres that
included more than 1 patient. Only centres that had
included more than 5 patients actually contributed to this
retrospective study. These centres treated 252 patients in
total, among which 181 patient files (71%) were collected
and updated as of March 20th, 2012. 181 of the 328 (55%)
patients of the ATU program are therefore included in this
report. Trabectedin was given at the standard schedule of
1.5 mg/m2 in 24 h continuous infusion every 21 days, as
previously reported, with dose adaptations similar to those
applied in the protocols [19-23].
Objectives
The primary objective of this study was to evaluate
progression-free survival, while secondary endpoints were
response rates, duration of response, overall survival, tox-
icity leading to hospital rehospitalisation, description of
the patient populations, impact of treatment duration on
treatment efficacy. Because of its retrospective nature, only
very simple clinical parameters were collected.
Inclusion criteria for the retrospective study
These criteria were those from the EORTC trial [23], the
largest of the single-arm phase II studies with trabectedin.
Patients had to have a documented progressive disease at
inclusion). No concurrent antitumor therapy was allowed.
Other eligibility criteria were age older than 18 years;
performance status 0 or 1; no functionally important car-
diovascular disease, no prior cancer (except adequately trea-
ted in situ carcinoma of cervix or basal cell carcinoma);
presence of measurable lesions not previously irradiated,
no central nervous system metastases; adequate bone mar-
row reserve (neutrophils > 2,000/mm3, platelet count >
100,000/mm3); and adequate renal and hepatic functions:
serum creatinin less than 120 μmol/L or calculated creati-
nin clearance (Cockroft method) greater than 60 mL/min,
bilirubin > 30 μmol/L, AST and ALT less than 1.5 U/L
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less than 2.5 U/L and albumine > 25 g/L. Mesothelioma,
chondrosarcoma, neuroblastoma, osteosarcoma, Ewing’s
sarcoma, embryonal rhabdomyosarcoma, and dermatofi-
brosarcoma were excluded.
Case report form
A simple Case Report Form with 22 items was used to
collect patients’ characteristics and outcome. Information
has been collected on an excel spreadsheet, consolidated
in an Excel database, and then analyzed using the SPSS
12.1 software by institutional data manager. Collected
information included the following: anonymized patient
identity, centre, date of birth, gender, date of diagnosis,
histotype, grade, date of metastasis, description of first/
s/>2 line treatments, best response, duration, date of
trabectedin first course, ECOG PS at that date, meta-
static sites at that date (lung, liver, local, soft part, bone,
or other), number of cycles, best response to trabecte-
din, toxicity of trabectedin requiring re-admission, date
of last course of trabectedin, date of progression after
trabectedin, treatment after trabectedin and best response,
date of death. Optional data were number of available path-
ology tissue block, and contact information for the path-
ology department where diagnosis was made and which
held the pathology samples.
Descriptive analysis and statistics
Baseline demographics and clinical outcome statistical
analyses were based on all data available up to the cut-off
date of December, 31st 2011. Descriptive statistics were
used to depict the variables distribution. Follow-up was
calculated from course 1 of trabectedin. Progression-free
survival (PFS) was defined as the interval between the
date of the first trabectedin cycle and the date of disease
progression, death, or last follow-up contact. The inter-
val between the date of the first cycle of trabectedin and
the time of death or last follow-up defined the Overall
Survival (OS). PFS and OS rates were estimated using
the Kaplan-Meier method and were compared using the
log-rank test. Univariate analyses included the following
variables: age; sex; performance status; grade; histological
subtype; disease location, myxoid liposarcoma histology,
translocation sarcoma, treatment line, hospitalization for
toxicity and liver/lung metastases. Responses were deter-
mined retrospectively using RECIST 1.1. All statistical tests
were 2-sided, and a p-value below 0.050 was considered
statistically significant. This study was approved by the local
institutional review board at each participating institution.
Results
Population and patient characteristics
Between 2003 and 2008, 87 centres have included 328
patients in the ATU program. The present study wasperformed on 181 patients from 11 centres having trea-
ted at least 5 patients who agreed to participate. This
represents 55% of the total cohort of 328 ATU patients.
Inclusion criteria of the ATU were those of the EORTC
trial. The only difference was that no restrictions were
imposed on the previous number of lines. The median
number of patient per centre was 17 (range 5 to 32).
Patients’ characteristics are described in Table 1. 29% had
translocation-related sarcomas. At diagnosis, grade 3, 2
and 1 STS represented 44%, 28% and 9% of the tumors
respectively. Median line of therapy was third line for tra-
bectedin, with a range of 1 to 4 lines. 56 of 181 patients
(31%) received 6 cycles or more. During the course of
treatment, 30 (17%) of the patients had to be re-admitted
for treatment-related adverse events.
Survival
With a median follow-up of 64 months after initiation of
trabectedin treatment, the median PFS was 3.6 months,
with a 6-months PFS rate of 39%. Median OS survival
was 16.1 months, with 3, 4, and 5 years OS rate of 23%,
15%, and 4% respectively (Figure 1A and 1C). PFS and
OS were superior in patients treated in 1st and 2nd line
but prolonged survival >24 months was observed in all
subgroups (Figure 1B, and 1D). PFS was superior in
patients with myxoid liposarcomas, retroperitoneal sarco-
mas and grade 1 tumors (Table 1). OS was superior in
patients with myxoid liposarcomas, retroperitoneal sarco-
mas and grade 1 tumors (Table 1). In multivariate analysis,
the only two independent prognostic factors identified for
PFS were histological subtype of myxoid LPS and the line
of treatment. For OS, the two favorable prognostic factors
in multivariate analysis were histological subtype of myx-
oid liposarcomas and retroperitoneal locations for primary
disease (Table 2).
Response to treatment
Partial response (PR), stable disease (SD), and progres-
sive disease (PD) were recorded as best response in 10%,
39%, 46% of the patients respectively, with 5% patients
being non evaluable. No significant difference was were
observed according to the line of trabectedin administra-
tion (Table 3, p = 0.17). Myxoid liposarcoma had a better
response and stable disease rate (21% and 54% respect-
ively) as compared to other histological types (8% and 36%
respectively) (p = 0,002) with no significant difference
between other translocation-related sarcomas and the
remaining group of sarcoma (not shown). The median
duration of response was 10.5 months (95% CI: 5.4–15.6).
Overall survival of partial responders and patients with
SD were similar in the first years, but only partial respon-
ders were long-term survivors beyond 5 years (44%).
Overall survival of patients with PR or SD subgroups,
were equivalent, and both superior to that of patients
Table 1 Patients characteristics and survival
N (%) Median OS Median PFS
months logrank months logrank
Age 47 (15–84)
<=60 145 (80) 16.9 0.05 3.3 0,13
>60 36 (20) 11.7 3.0
Male 83 (46) 14,7 0.36 3.8 0,78
Female 98 (54) 16,6 3.1
Site
Inf limb 59 (33) 17.1 0.15 4.8 0.03
Sup Limb 12 (7) 16.6 2.3
Retroperitoneum 33 (18) 19.6 9.1
Uterus 24 (13) 13.9 3.0
Other trunk 45 (25) 9.3 2.7
Head/Neck 8 (4) 17.0 4.0
Histotypes
LMS 55 (30) 17,4 0.005 3.4 0.005
Myxoid LPS 28 (16) 33.4 10,5
LPS (other) 21 (11) 20.0 3.2
NOS/undiff. 22 (12) 14,0 2.2
Synovial 16 (9) 9.2 4.0
Others/Misc 39 (22) 6.7 2.1
Myxoid LPS
Yes 28 (15) 33.4 0.01 10,5 0.000
No 153 (85) 13.9 2.8
Translocation sarcomas
Yes 54 (30) 15.3 0.17 5.3 0,02
No 119 (66) 14.7 2.8
Grade
1 17 (9) 16.9 0.43 9.7 0,17
2 51 (28) 18.6 4.4
3 80 (44) 16.0 3.6
UNK 33 (19) 10.7 2.8
Treatment line for ET-743 (median: 3, range 1–4)
1* 10 (6) 33.4 0.03 4.5 0.04
2 67 (37) 18.2 5.3
3 60 (33) 14.3 3.2
4 42 (23) 10.2 2.8
* doxorubicin and ifosfamide in the adjuvant setting
Hospitalisation for toxicity (reported in N = 152)
Yes 30 (17) 6.7 0.03 2.5 0.39
No 122 (65) 18.2 4.5
Lung metastases
Yes 128 (71) 14.7 0.93 3.0 0.054
No 47 (25) 16.9 6.7
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Table 1 Patients characteristics and survival (Continued)
Liver metastases
Yes 45 (25) 16.8 0.51 3.0 0.83
No 125 (70) 13.5 3.6
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response (Figure 2).
Maintenance therapy after 6 cycles
A total of 56 (31.1%) patients were in SD or PR after
6 cycles. In 16, the treatment was stopped, whereas in
40 patients it was continued beyond 6 cycles for a me-
dian of 9 cycles (range 7–19). The subgroup of patients
treated with 7 or more cycles had a significantly better
PFS (median 5.3 months vs 10,5 months, p = 0,001) and
OS (median 13,9 vs 33,4 months p = 0.009) (Figure 3)
than the other subgroup, suggesting that maintenance).A
C
Figure 1 Progression-free and overall survival of the cohort according
cohort. B: Progression-free survival of patients treated in first (blue), second
p = 0,043). C: Overall survival in the whole cohort. D: Overall survival of pat
(purple) line of treatment (logrank, p = 0,018).Maintenance therapy was associated with a better PFS
and OS in this series analyzed retrospectively.
Discussion
The objective of this retrospective study was to assess
the outcome of STS patients treated in the French ATU
compassionate use program and to compare it with that
of published clinical trials. Between 2003 and 2008, this
program enabled the treatment of patients failing doxo-
rubicin with trabectedin 1.5 mg/m2/21d. The inclusion
criteria were the same than those of the EORTC trial,
with the exception that all lines were allowed.B
D
to the number of lines. A: Progression-free survival in the whole
(green), third (light brown) or >3 (purple) line of treatment (log-rank,
ients treated in first (blue), second (green), third (light brown) or >3
Table 2 Multivariate prognostic analysis for PFS and OS
beta E.S. Signif. HR
PFS Myxoid LPS −0.544 0.284 0.056 0.580
Line of treatment 0.272 0.117 0.020 1.312
OS Myxoid LPS −0.970 0.241 0.000 0.379
Retroperitoneal STS −0.524 0.209 0.012 0.592
Figure 2 Overall survival according to the best response to
trabectedin. Overall survival of patients whose best response was:
partial response (light brown), stable disease (purple), progressive
disease (green), or non evaluable (blue). Log-rank p value, p < 0,0001.
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ally only centres that included more than 5 patients con-
tributed to this analysis, and these included 181 patients
in this retrospective study. This series represents therefore
a selected subgroup of patients treated mostly in reference
centres for sarcoma, and in experienced centres regarding
trabectedin usage. Among the 11 centres participating to
the study, 5 had participated to the phase II EORTC trial,
reflecting the experience of the centres with this agent.
This is therefore a selected subgroup of the ATU series,
but this selection makes comparison with phase II data
maybe more relevant. It would have been of interest to
compare this series to that of patients treated in non-
expert centres but this could not be obtained. In this
group of 181 heavily pretreated STS sarcoma patients,
either resistant or relapsing, trabectedin was received as
a second line therapy for a majority of them and some
patients received the treatment in 4th line. This is a
more heavily pretreated patient population than that of
the EORTC trials. Despite of this, the response rate (10%),
stable disease rate (39%), PFS (median 3.6 months) and
OS (median 16.1 months) were comparable to those
observed with trabectedin in the phase II trials. Accord-
ing to the EORTC-STBSG (European Organisation for
Research and Treatment of Cancer- Soft Tissue and
Bone Sarcoma Group) criteria, because the 3-months
progression free rate was largely superior to 40% and
the 6-monthz PFR was superior to the threshold used to
define an active treatment according to the EORTCTable 3 Response to trabectedin according to the line of
treatment
Best response to trabectedine Total
NE PD SD PR
Line of treatment 1 N 0 3 4 3 10
% ,0% 30,0% 34,0% 30,0% 100,0%
2 N 1 32 26 8 67
% 1,5% 47,8% 38,8% 11,9% 100,0%
3 N 4 26 27 3 60
% 6,7% 43,3% 45,0% 5,0% 100,0%
4 N 4 22 12 4 42
% 9,5% 52,4% 28,6% 9.5% 100,0%
Total N 9 83 69 18 179
% 5,0% 46,4% 38,5% 10,1% 100,0%STBSG [5]. It is however challenging to compare the
present series with the EORTC database of the pre-
trabectedin era [2,3] published since 1999 for several
reasons : 1) the former series included mainly first line
patients, while the present series gathers patients in all
lines (from first line metastatic in patients pretreated
in the adjuvant setting to fourth line patients. 2) histo-
logical classifications and inclusion criteria varied con-
siderably between the 2 series; for instance, GIST were
mixed amongst leiomyosarcoma in the former series.
The exhaustive histological reviews of the former series
were has not performed with the classifications of 2002
or 2013.
Possibly the best comparison can be obtained with the
subsequent paper by Van Glabbeke et al., reporting separ-
ately second line + patients. In this case, the median pro-
gression free rate is 2.3 months, and a 1 year PFR rate of
7% in the whole series, and 12% for the series of patients
treated with “active agents” [5]. The results observed with
the present ATU series, median PFS of 3,6 months, and
12 months PFS close to 30% compare therefore favorably
with these historical controls, despite all these limitations.
Detailed side-effects of trabectedin treatment were not
collected in this retrospective study. Only toxicity leading
to hospitalization was documented and remained limited,
affecting only 17% of patients. As expected these patients
had a smaller number of cycles delivered and, perhaps
as a consequence, had a worse PFS. Overall survival was
however not significantly different than that of on patients
AB
Figure 3 Progression-free and overall survival according to
maintenance after 6 cycles. No maintenance- treatment
interruption after 6 cycles (blue); maintenance- treatment beyond
6 cycles (green). Log-rank p-value for PFS, p = 0,007; Log-rank for
OS, p = 0,0002.
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cities do not lead to rehospitalisation, no formal conclusion
can be proposed on a possible lack of correlation with
therapeutic efficacy, considering also the limited number of
patients in this series.
As previously described, patients with myxoid liposar-
comas had better response rates, PFS,OS, and was an in-
dependent prognostic factor for survival. The number oflines of chemotherapy administered before trabectedin
also correlated significantly with longer PFS in the Cox
model, but not for OS. Conversely, retroperitoneal loca-
tion was were associated with a improved survival, possibly
because of the low grade and loco-regional behavior; most
are liposarcomas, a subset associated with a better outcome
in large retrospective datasets in the present series as well
[2]. Interestingly, OS and PFS of translocation-related sar-
comas excluding myxoid liposarcoma was not different of
that of other sarcoma types. Similar observations were
made for response rate (not shown).
Thirty percent of the patients in the present study
received more than 6 cycles of trabectedin, which under-
lines an acceptable toxicity profile allowing prolonged
treatment. Long-term treatment is feasible with trabecte-
din, while this is not feasible with doxorubicin nor ifosfa-
mide because of cumulative cardiac and renal toxicities.
Prolonged trabectedin treatment thus allows testing the
importance of maintenance treatment. Interestingly, among
the 56 patients who were not progressing after 6 cycles, the
40 who continued treatment had a significantly better PFS
and more surprisingly OS, with a more than doubling of
the median OS. The retrospective nature of the study
implies potentials biases in these observations, and there-
fore this cannot be considered as an evidence for the
utility of prolonged treatment. However, these observa-
tions strengthen the rationale of the ongoing study ran-
domizing treatment maintenance vs interruption after
6 cycles which is currently ongoing within the French
Sarcoma Group (NCT01303094). It has previously been
shown in a large randomized clinical trial (SUCCEED)
that maintenance with an mTOR inhibitor enables to
prolong PFS, but not OS (Demetri et al. submitted for
publication). Maintenance therapy maybe a strategy worth
further exploring in patients with advanced STS.Conclusion
In conclusion, this retrospective analysis of 55% of the
advanced sarcoma patients treated in France in the com-
passionate use program shows that the use of trabectedin
in routine clinical practice, in large volume centres, yields
an outcome similar to the previously observed results in
earlier clinical trials. Trabectedin is confirmed as an active
and safe agent for the treatment of advanced STS patients
who have failed to standard therapies. Patients treated
beyond 6 cycles of trabectedin had a significantly better
survival, pointing out a potential role of maintenance
treatment. An exhaustive retrospective study collecting
the information on all patients treated with trabectedin
since its approval could be very helpful to describe the
outcome of patient populations in low volume centres.
A prospective studies is ongoing to evaluate the efficacy
of maintenance after 6 cycles.
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